請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77593
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 盧子彬(Tzu-Pin Lu) | |
dc.contributor.author | Ya-Chi Yeh | en |
dc.contributor.author | 葉雅琪 | zh_TW |
dc.date.accessioned | 2021-07-10T22:10:34Z | - |
dc.date.available | 2021-07-10T22:10:34Z | - |
dc.date.copyright | 2018-10-09 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-07-30 | |
dc.identifier.citation | 1. Franco, E., et al., EKG pattern of Brugada syndrome and sudden infant death syndrome--is it time to review the diagnostic criteria? Case report and review of literature. Ann Noninvasive Electrocardiol, 2014. 19(2): p. 198-202.
2. Benito, B., et al., Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol, 2008. 52(19): p. 1567-73. 3. Kamakura, S., Epidemiology of Brugada syndrome in Japan and rest of the world. Journal of Arrhythmia, 2013. 29(2): p. 52-55. 4. Brugada, J., P. Brugada, and R. Brugada, The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome. Europace, 1999. 1(3): p. 156-66. 5. Matsuo, K., et al., The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J, 1999. 20(6): p. 465-70. 6. Mizusawa, Y. and A.A. Wilde, Brugada syndrome. Circ Arrhythm Electrophysiol, 2012. 5(3): p. 606-16. 7. Berne, P. and J. Brugada, Brugada syndrome 2012. Circ J, 2012. 76(7): p. 1563-71. 8. Oe, H., et al., Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese population. Pacing Clin Electrophysiol, 2005. 28(6): p. 549-54. 9. Antzelevitch, C., Brugada syndrome. PACE - Pacing and Clinical Electrophysiology, 2006. 29(10): p. 1130-1159. 10. Eckardt, L., Gender differences in Brugada syndrome. Journal of Cardiovascular Electrophysiology, 2007. 18(4): p. 422-424. 11. Straus, S.M., et al., The incidence of sudden cardiac death in the general population. J Clin Epidemiol, 2004. 57(1): p. 98-102. 12. Watanabe, H. and T. Minamino, Genetics of Brugada syndrome. Journal Of Human Genetics, 2015. 61: p. 57. 13. Brugada, P., R. Brugada, and J. Brugada, The brugada syndrome. Current Cardiology Reports, 2000. 2(6): p. 507-514. 14. Nademanee, K., et al., Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation, 1997. 96(8): p. 2595-2600. 15. Probst, V., et al., Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation, 2010. 121(5): p. 635-43. 16. Barros, M.A.L., et al., Brugada syndrome in a family with a high mortality rate: a case report. Journal of Medical Case Reports, 2013. 7: p. 78-78. 17. Chen, Q., et al., Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature, 1998. 392(6673): p. 293-296. 18. Deschênes, I., et al., Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovascular Research, 2000. 46(1): p. 55-65. 19. Vatta, M., et al., Novel mutations in domain I of SCN5A cause Brugada syndrome. Molecular Genetics and Metabolism, 2002. 75(4): p. 317-324. 20. Kapplinger, J.D., et al., An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm, 2010. 7(1): p. 33-46. 21. Juang, J.M.J. and M. Horie, Genetics of Brugada syndrome. J Arrhythm, 2016. 32(5): p. 418-25. 22. Bezzina, C.R., et al., Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet, 2013. 45(9): p. 1044-9. 23. Priori, S.G., et al., Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation, 2000. 102(20): p. 2509-15. 24. Probst, V., et al., SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet, 2009. 2(6): p. 552-7. 25. Schulze-Bahr, E., et al., Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat, 2003. 21(6): p. 651-2. 26. Hermida, J.S., et al., Prospective evaluation of the familial prevalence of the brugada syndrome. Am J Cardiol, 2010. 106(12): p. 1758-62. 27. Alings, M. and A. Wilde, “Brugada” Syndrome. Clinical Data and Suggested Pathophysiological Mechanism, 1999. 99(5): p. 666-673. 28. Juang, J.M., et al., Unique clinical characteristics and SCN5A mutations in patients with Brugada syndrome in Taiwan. J Formos Med Assoc, 2015. 114(7): p. 620-6. 29. Kapplinger, J.D., et al., An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm, 2010. 7(1): p. 33-46. 30. Watanabe, H., et al., Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest, 2008. 118(6): p. 2260-8. 31. Riuro, H., et al., A missense mutation in the sodium channel beta2 subunit reveals SCN2B as a new candidate gene for Brugada syndrome. Hum Mutat, 2013. 34(7): p. 961-6. 32. Hu, D., et al., A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet, 2009. 2(3): p. 270-8. 33. Hu, D., et al., Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol, 2014. 64(1): p. 66-79. 34. Kattygnarath, D., et al., MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet, 2011. 4(3): p. 261-8. 35. London, B., et al., Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation, 2007. 116(20): p. 2260-8. 36. Ishikawa, T., et al., A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene mutations impair intracellular trafficking of hNav1.5. Circ Arrhythm Electrophysiol, 2012. 5(6): p. 1098-107. 37. Cerrone, M., et al., Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation, 2014. 129(10): p. 1092-103. 38. Liu, H., et al., Molecular genetics and functional anomalies in a series of 248 Brugada cases with 11 mutations in the TRPM4 channel. PLoS One, 2013. 8(1): p. e54131. 39. Abbott, G.W. and S.A. Goldstein, Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. Faseb j, 2002. 16(3): p. 390-400. 40. Abbott, G.W., et al., MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell, 1999. 97(2): p. 175-87. 41. Wang, Q., et al., Gain-of-function KCNH2 mutations in patients with Brugada syndrome. J Cardiovasc Electrophysiol, 2014. 25(5): p. 522-30. 42. Visscher, P.M., et al., 10 Years of GWAS Discovery: Biology, Function, and Translation. American Journal of Human Genetics, 2017. 101(1): p. 5-22. 43. Antzelevitch, C., et al., Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation, 2005. 111(5): p. 659-70. 44. Wilde, A.A., et al., Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J, 2002. 23(21): p. 1648-54. 45. Antzelevitch, C., et al., Brugada syndrome: report of the second consensus conference. Heart Rhythm, 2005. 2(4): p. 429-40. 46. Abdi, H. and L.J. Williams, Principal component analysis. Wiley Interdisciplinary Reviews: Computational Statistics, 2010. 2(4): p. 433-459. 47. Purcell, S., et al., PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet, 2007. 81(3): p. 559-75. 48. Li, Y., et al., Genotype imputation. Annu Rev Genomics Hum Genet, 2009. 10: p. 387-406. 49. Howie, B.N., P. Donnelly, and J. Marchini, A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies. PLOS Genetics, 2009. 5(6): p. e1000529. 50. The Genomes Project, C., A global reference for human genetic variation. Nature, 2015. 526(7571): p. 68-74. 51. Visscher, P.M., Sizing up human height variation. Nat Genet, 2008. 40(5): p. 489-90. 52. Manolio, T.A., et al., Finding the missing heritability of complex diseases. Nature, 2009. 461(7265): p. 747-53. 53. Eichler, E.E., et al., Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet, 2010. 11(6): p. 446-50. 54. Wu, Michael C., et al., Rare-Variant Association Testing for Sequencing Data with the Sequence Kernel Association Test. American Journal of Human Genetics, 2011. 89(1): p. 82-93. 55. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science, 2015. 348(6235): p. 648-660. 56. Tabas-Madrid, D., R. Nogales-Cadenas, and A. Pascual-Montano, GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res, 2012. 40(Web Server issue): p. W478-83. 57. Kumar, P., S. Henikoff, and P.C. Ng, Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc, 2009. 4(7): p. 1073-81. 58. Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 7(4): p. 248-9. 59. Bespalova, I.N. and M. Burmeister, Identification of a novel LIM domain gene, LMCD1, and chromosomal localization in human and mouse. Genomics, 2000. 63(1): p. 69-74. 60. Safran, M., et al., GeneCards™ 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics, 2002. 18(11): p. 1542-1543. 61. Greenlees, R., et al., Mutations in SIPA1L3 cause eye defects through disruption of cell polarity and cytoskeleton organization. Hum Mol Genet, 2015. 24(20): p. 5789-804. 62. Kanie, T., et al., The CEP19-RABL2 GTPase Complex Binds IFT-B to Initiate Intraflagellar Transport at the Ciliary Base. Dev Cell, 2017. 42(1): p. 22-36.e12. 63. Peacock, J.D., et al., Temporal and spatial expression of collagens during murine atrioventricular heart valve development and maintenance. Dev Dyn, 2008. 237(10): p. 3051-8. 64. Dunn, C., et al., Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal, 2002. 14(7): p. 585-93. 65. Francois, A.A., et al., Loss of Protein Kinase Novel 1 (PKN1) is associated with mild systolic and diastolic contractile dysfunction, increased phospholamban Thr17 phosphorylation, and exacerbated ischaemia-reperfusion injury. Cardiovasc Res, 2018. 114(1): p. 138-157. 66. Rath, N., et al., LMCD1/Dyxin is a novel transcriptional cofactor that restricts GATA6 function by inhibiting DNA binding. Mol Cell Biol, 2005. 25(20): p. 8864-73. 67. Xin, M., et al., A threshold of <em>GATA4</em> and <em>GATA6</em> expression is required for cardiovascular development. Proceedings of the National Academy of Sciences, 2006. 103(30): p. 11189-11194. 68. Bian, Z.-Y., et al., LIM and Cysteine-Rich Domains 1 Regulates Cardiac Hypertrophy by Targeting Calcineurin/Nuclear Factor of Activated T Cells Signaling. Hypertension, 2010. 55(2): p. 257-263. 69. Takagi, H., et al., Activation of PKN mediates survival of cardiac myocytes in the heart during ischemia/reperfusion. Circulation research, 2010. 107(5): p. 642-649. 70. McPherson, R., et al., A Common Allele on Chromosome 9 Associated with Coronary Heart Disease. Science, 2007. 316(5830): p. 1488-1491. 71. Samani, N.J., et al., Genomewide association analysis of coronary artery disease. N Engl J Med, 2007. 357(5): p. 443-53. 72. Helgadottir, A., et al., A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. Science, 2007. 316(5830): p. 1491-1493. 73. Ragione, F.D. and A. Iolascon, Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias. Leuk Lymphoma, 1997. 25(1-2): p. 23-35. 74. Kojima, Y., et al., Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest, 2014. 124(3): p. 1083-97. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77593 | - |
dc.description.abstract | 背景:布魯蓋達症候群為一心臟遺傳罕見疾病,此疾病會造成心臟電流出現異常而導致猝死。布魯蓋達症候群全世界盛行率約0.01-0.05%,其中亞洲地區又高於其他地區國家。目前布魯蓋達症候群被認為是體染色體顯性遺傳疾病,其中SCN5A基因變異為主要的危險因子,但在臨床上僅有20%的病人帶有SCN5A基因突變,這表示了有超過75%的病人,其致病過程仍然未知。過去,有研究針對歐洲族群進行布魯蓋達症候群全基因體關聯性研究,其研究結果顯示,在歐洲族群中有兩個顯著的遺傳變異位點(rs10428132及rs9388451)。然而,由於族群和地域間的布魯蓋達症候群發病機率有所差異,因此,本研究預期針對台灣病患資料找出重要的遺傳多型性位點,並驗證過去所報導的布魯蓋達症候群相關遺傳變異,以提供在布魯蓋達症候群的遺傳機制及致病機轉更進一步的了解。
研究方法:本研究之病例組來自於全台灣各地醫療院所,共190個病人,正常對照組資料來源為台灣人體生物自料庫,共15981人。利用Axiom Genome_Wide TWB Array Plate (Affymetrix)微陣列晶片進行基因型鑑定。使用費雪精確檢定針對相加、顯性及隱性模式進行單一位點分析,接著利用表達數量性狀基因座分析評估遺傳變異在心臟組織間的基因表現,並進行基因組富集分析以探討遺傳變異的傳導途徑及生物功能性,另外,使用SIFT及PolyPhen-2兩種生物資訊演算法針對錯義突變位點進行蛋白質功能預測。多位點分析則使用序列核關聯檢定以評估多個位點同時對疾病的影響。最後,利用基因插補法獲得其中一個過去研究所發現之遺傳變異位點資訊,以供後續驗證。 結果:經質量控管後,共有190病例組及14274正常對照組進行後續分析,其中共有21個位點在三個遺傳模式下皆顯著(病例組及對照組次要等位基因頻率差異> 0.3以上),rs9875641位點變異與心臟組織中LMCD1-AS1基因表現有顯著相關性,而rs34726907位點變異與RABL2B及AC002055.4基因表現有顯著相關性。四個錯義突變位點rs751074523、rs373144666、rs760608934及rs758378155在兩種演算法預測下,至少有一演算法預測該位點突變可能對蛋白質功能造成有害影響。在多位點分析結果中,共有10個基因對布魯蓋達症候群具有顯著影響。過去歐洲研究所發現的兩個布魯蓋達症候群遺傳變異在台灣族群中亦獲得驗證。 結論:本研究發現了許多在台灣族群中特有的布魯蓋達症候群相關遺傳變異,未來仍需要透過其它外部資料進行驗證。研究結果有助於了解布魯蓋達症候群致病機轉及生物傳導途徑,以協助未來尋找布魯蓋達症候群早期診斷的生物標記及藥物開發上提供參考依據。 | zh_TW |
dc.description.abstract | Background: Brugada syndrome (BrS) is a rare disease that has a high risk causing sudden cardiac death due to the ventricular fibrillation. The prevalence of BrS is estimated to be 1-5 cases per 10,000 people, and its incidence and prevalence rates are higher in the Asian populations. Currently, BrS is considered as an autosomal dominant disorder, and SCN5A is the major genetic risk factor. However, only 20% of BrS patients can be attributed to SCN5A, which means that the pathogenic process of more than 75% BrS patients remains unclear. Two loci (rs10428132 and rs9388451) were reported in the previous GWAS in the European patients. Therefore, the aim of this study is to identify novel SNP loci associated with BrS in Taiwanese population.
Materials and Methods: A total of 190 BrS cases were recruited from hospitals and medical centers in Taiwan, and 15,981 healthy controls were obtained from Taiwan Biobank. The genotyping experiments were performed by using the Axiom Genome_Wide TWB Array Plate (Affymetrix). A Fisher exact test based on the three genetic models (additive, dominant, recessive) were used to evaluate the effect of a SNP locus. We further evaluated the expression quantitative trait loci (eQTL) of selected SNPs in heart tissue. Gene set enrichment analysis was used to characterize enriched biological pathways and molecular functions. Two bioinformatics algorithms (SIFT, Polyphen2) were used to evaluate the functional impact of identified missense variants. Furthermore, the Sequence Kernel Association Test (SKAT) algorithm was used to evaluate the combination effects of multi-markers. Lastly, we performed an imputation study based on the allele frequencies obtained from the East Asian populations in the 1000 genome project in order to obtain the genetic information of one validated SNP locus. Results: There were 190 cases and 14,274 controls passing the quality control steps. A total of 21 SNPs were significant in three genetic models (MAF differences between case and control > 0.3). The SNP, rs9875641 was associated with expression of LMCD1-AS1. The SNP, rs34726907 was associated with expression of RABL2B and AC002055.4 in heart tissue. The 4 SNPs, including rs751074523、rs373144666、rs760608934 and rs758378155 were predicted as possibly damaging variants by at least one bioinformatics algorithm from SIFT and PolyPhen-2. The SKAT approach reported the 10 genes associated with BrS according to their combined effects of multi-markers. Two loci rs10428132(SCN10A) and rs9388451(HEY2) reported in a previous GWAS study in European patients were also significantly associated with BrS in Taiwanese population. Conclusions: We find some common genetic variants in the BrS patients specific to Taiwanese population. However, further replication in different datasets is warranted to validate our findings. The novel DNA loci can provide a better understanding of BrS etiology, and these findings may provide new insights of the diagnosis and treatment in BrS in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T22:10:34Z (GMT). No. of bitstreams: 1 ntu-107-R05849026-1.pdf: 5032269 bytes, checksum: 7a84de65b1cdc9ca953f1188126db074 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iv 第一章 前言 1 第一節 研究背景 1 第二節 研究動機及重要性 1 第三節 研究目的 4 第二章 文獻回顧 5 第一節 布魯蓋達症候群族群間差異 5 第二節 布魯蓋達症候群相關基因 5 第三節 全基因體關聯性研究(Genome-wide association study, GWAS) 7 第四節 布魯蓋達症候群全基因體關聯性研究 8 第三章 方法及材料 9 第一節 研究對象 9 第二節 資料蒐集 10 第三節 質量控管(Quality Control, QC) 12 第四節 統計分析 13 第五節 基因插補法(Genetic Imputation) 13 第六節 序列核關聯檢定(Sequence Kernel Association Test, SKAT) 14 第七節 多基因遺傳風險評分(polygenic risk score, PRS) 15 第八節 表現量及基因富集分析 16 第九節 功能預測分析 16 第四章 結果 18 第一節 人口學變項分布 18 第二節 質量控管 18 第三節 全基因體關聯性分析 19 第四節 表現量及基因富集分析 19 第五節 功能預測分析 21 第六節 序列核關聯檢定 21 第七節 驗證過去研究 22 第五章 討論與結論 23 第一節 主要發現 23 第二節 研究限制 25 第三節 公共衛生與臨床意義 25 參考文獻 27 | |
dc.language.iso | zh-TW | |
dc.title | 台灣布魯蓋達症候群全基因體關聯性研究 | zh_TW |
dc.title | A genome-wide association study identifies susceptibility loci for Brugada syndrome in Taiwanese patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭朱杏(Chuhsing Kate Hsiao),陳為堅(Wei J. Chen),林菀俞(Wan-Yu Lin),莊志明(JYH-MING Jimmy JUANG) | |
dc.subject.keyword | 布魯蓋達症候群,全基因體關聯性研究, | zh_TW |
dc.subject.keyword | Brugada syndrome,GWAS, | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU201801689 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-07-31 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R05849026-1.pdf 目前未授權公開取用 | 4.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。